ZEALAND PHARMA/S (NASDAQ:ZEAL) will be announcing its earnings results before the market opens on Thursday, May 16th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter.
ZEALAND PHARMA/S (NASDAQ:ZEAL) last released its earnings results on Thursday, March 7th. The company reported ($0.61) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.08. The company had revenue of $2.01 million for the quarter. On average, analysts expect ZEALAND PHARMA/S to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
ZEAL opened at $20.20 on Thursday. The firm has a market cap of $621.90 million, a PE ratio of 6.73 and a beta of 2.40. ZEALAND PHARMA/S has a 52-week low of $11.51 and a 52-week high of $20.83.
Several analysts have recently issued reports on ZEAL shares. Needham & Company LLC reissued a “buy” rating and set a $29.00 target price on shares of ZEALAND PHARMA/S in a report on Thursday, March 7th. Zacks Investment Research raised ZEALAND PHARMA/S from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a report on Saturday, April 27th. ValuEngine raised ZEALAND PHARMA/S from a “sell” rating to a “hold” rating in a report on Friday, January 11th. Finally, TheStreet raised ZEALAND PHARMA/S from a “d+” rating to a “c-” rating in a report on Tuesday, January 22nd. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $26.00.
ILLEGAL ACTIVITY WARNING: “ZEALAND PHARMA/S (ZEAL) Set to Announce Quarterly Earnings on Thursday” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at https://www.americanbankingnews.com/2019/05/09/zealand-pharma-s-zeal-set-to-announce-quarterly-earnings-on-thursday.html.
About ZEALAND PHARMA/S
Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua.
Further Reading: Can systematic risk be avoided?
Receive News & Ratings for ZEALAND PHARMA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZEALAND PHARMA/S and related companies with MarketBeat.com's FREE daily email newsletter.